First Tracks Biotherapeutics Inc

First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026

First Tracks Biotherapeutics (Nasdaq: TRAX) will host an investor call and webcast on Oct. 12, 2026, at 8:30am ET to review top-line data from Cohort 1 of the Phase 1b trial of ANB033, a CD122 antagonist, in celiac disease. Cohort 1 is a gluten-challenge study assessing prevention of mucosal damage; data will be issued in a morning press release and presented during the webcast. The company's pipeline also includes rosnilimab for rheumatoid arthritis and ANB101, a BDCA2 modulator.

•14d ago

First Tracks Biotherapeutics Announces Participation in September Investor Conferences

First Tracks Biotherapeutics announced that members of its executive team will participate in three investor conferences during September. The schedule includes a fireside chat and one-on-one meetings at the Wells Fargo Healthcare Conference on Sept. 9, followed by one-on-one meetings at Citi's 2026 Biopharma Back to School Conference on Sept. 10 and the Morgan Stanley Global Healthcare Conference on Sept. 16. A live webcast of the fireside chat will be accessible via the company's investor relations website, with a replay available for 30 days.

•1mo ago

First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences

First Tracks Biotherapeutics announced that CEO Daniel Faga and other executives will present at the Jefferies Global Healthcare Conference on June 3, 2026. The company also scheduled one-on-one investor meetings at the Leerink Partners Therapeutics Forum on July 14, 2026. A live webcast of the Jefferies presentation will be available on the company's investor relations website, with a replay accessible for 30 days.

•5mo ago

First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

First Tracks Biotherapeutics reported Q1 2026 financial results following its April 20 spin-off from AnaptysBio, ending the quarter with approximately $248 million in cash and equivalents. The company posted a net loss of $50.5 million, driven by $34 million in R&D and $18.9 million in G&A expenses, which include allocations from the separation process. Management highlighted a two-year cash runway to advance lead asset ANB033 through Phase 1b trials in celiac disease and eosinophilic esophagitis, with data expected in late 2026 and mid-2027. For rosnilimab, the company completed an End-of-Phase 2 meeting with the FDA and is assessing strategic options, including potential partnerships or out-licensing for rheumatoid arthritis development.

•5mo ago